Adult-onset autoimmune diabetes can resemble type 2 diabetes at first. Understanding the differences—and knowing which blood tests may help clarify the cause of high glucose—can support a more informed conversation with your healthcare provider.

Adults who develop high blood sugar are often assumed to have type 2 diabetes. That classification is correct for many people—but not for everyone.

Some adults have an autoimmune form of diabetes in which the immune system progressively attacks the pancreatic beta cells that produce insulin. This is adult-onset type 1 diabetes and, when the loss of insulin production progresses more slowly, it is often called latent autoimmune diabetes in adults, or LADA. The terminology is still debated, but the essential issue is the same: the underlying disease process is autoimmune rather than ordinary type 2 diabetes.^[1]

The distinction matters because A1C, fasting glucose, random glucose, and oral glucose tolerance testing can establish that diabetes is present, but those tests do not identify its cause. Islet autoantibodies and, in selected situations, C-peptide can provide information that helps a healthcare professional determine whether insulin-producing cells are being affected by autoimmunity.^[2]

Ulta Lab Tests provides direct online access to many relevant laboratory tests where available. Laboratory testing supplies information; it does not replace a diagnosis, treatment plan, or medical advice from a qualified healthcare provider. Direct-access testing should never delay emergency care for severe hyperglycemia or possible diabetic ketoacidosis.

Key Takeaways

• Type 1 diabetes can begin at any age, and adult symptoms may develop slowly enough to resemble type 2 diabetes.
• A1C and glucose tests can confirm diabetes but cannot determine whether it is autoimmune.
• The 2026 American Diabetes Association Standards identify GAD antibodies as the primary autoantibody to measure when adult type 1 diabetes is suspected.
• If GAD is negative but clinical suspicion remains, IA-2 and ZnT8 antibodies may provide additional evidence.
• C-peptide reflects the body’s remaining insulin production, but it must be interpreted with a concurrent glucose result and the circumstances of collection.
• Autoimmune diabetes can occur in people of any body size; no symptom, weight category, or single laboratory result proves the diagnosis.
• Severe thirst, vomiting, abdominal pain, deep breathing, confusion, or fruity-smelling breath may indicate diabetic ketoacidosis and require immediate medical evaluation.^[3]

In This Article

• What adult-onset autoimmune diabetes is
• Why correct classification matters
• When a type 2 diagnosis may not fit
• Diagnostic glucose thresholds
• Symptoms, risk factors, and warning signs
• The role of lab testing
• Related lab tests and biomarkers
• A practical testing approach
• How to understand results
• Frequently asked questions

What Is Adult-Onset Autoimmune Diabetes?

Direct answer: Adult-onset autoimmune diabetes is a form of type 1 diabetes that begins in adulthood. The immune system attacks insulin-producing pancreatic beta cells, causing insulin production to decline over time.

In classic type 1 diabetes, insulin production may fall rapidly. In LADA, beta-cell destruction may progress more slowly, and a person may not require insulin immediately after diagnosis. That delay is one reason LADA is frequently treated as type 2 diabetes at first.

Some people use the informal term “type 1.5 diabetes.” Although this phrase may help describe the apparent overlap, it is not a separate, universally defined diabetes category. The more precise description is slowly progressive adult-onset autoimmune diabetes or adult-onset type 1 diabetes.

Genes and environmental exposures may contribute to the autoimmune process, but adult-onset autoimmune diabetes is not caused simply by eating sugar, body weight, or a lack of exercise. At the same time, an individual with autoimmune diabetes may also have insulin resistance, overweight, or other metabolic risk factors. Body size alone therefore cannot classify the disease.^[4]

Why Correct Diabetes Classification Matters

The immediate concern is severe insulin deficiency. When the body does not have enough insulin to use glucose for energy, it begins breaking down fat and producing ketones. Excess ketones can lead to diabetic ketoacidosis, or DKA, a potentially life-threatening emergency.

Over the longer term, all forms of diabetes can affect the heart, blood vessels, kidneys, eyes, nerves, teeth, and feet. Autoimmune diabetes can also cluster with autoimmune thyroid disease, celiac disease, and pernicious anemia or vitamin B12 deficiency. Correct classification helps a healthcare professional select an appropriate monitoring and management pathway.^[4]

Classification is not merely a label. It may influence:

• How urgently insulin deficiency is addressed
• Which medications are appropriate
• Whether ketone and DKA education is needed
• How glucose changes are monitored
• Whether related autoimmune conditions should be investigated
• How symptoms such as fatigue, neuropathy, digestive problems, or declining exercise performance are evaluated

When a Type 2 Diabetes Diagnosis May Not Fit

Direct answer: Autoimmune diabetes may deserve consideration when an adult experiences rapid glucose deterioration, unintended weight loss, a short-lived response to typical type 2 treatment, an unexpectedly early need for insulin, ketones, DKA, or a personal or family history of autoimmune disease.

Patterns worth discussing with a healthcare provider include:

• Unintended weight loss or a relatively lean body composition
• Rapidly rising glucose or A1C
• Large glucose swings despite consistent habits
• Little or short-lived improvement with a typical type 2 approach
• Need for insulin sooner than expected
• Ketones or a history of DKA
• Autoimmune thyroid disease, celiac disease, pernicious anemia, or another autoimmune disorder
• Persistent digestive symptoms, nutrient deficiencies, or unexplained anemia
• A diabetes diagnosis that remains uncertain after routine testing

None of these features proves LADA. Conversely, the absence of these features does not rule it out. Some adults with autoimmune diabetes have overweight, metabolic syndrome, or a gradual clinical course.

Diagnostic Glucose Thresholds

The following thresholds apply to nonpregnant adults. Unless hyperglycemia is unequivocal or a random glucose result occurs with classic symptoms, an abnormal result is generally confirmed with repeat or complementary testing.^[2]

Laboratory test	Result in the diabetes range
A1C	6.5% or higher
Fasting plasma glucose	126 mg/dL or higher
Two-hour glucose during a 75-gram OGTT	200 mg/dL or higher
Random plasma glucose with classic symptoms	200 mg/dL or higher

A1C estimates average glucose over approximately three months, but it does not identify the type of diabetes. Iron deficiency, altered red-blood-cell survival, kidney failure, liver disease, blood loss or transfusion, pregnancy, and some hemoglobin variants can make A1C less reliable or create disagreement between A1C and measured glucose.^[2]

Common Symptoms, Risk Factors, and Warning Signs

Symptom or pattern	What it may suggest	Related laboratory tests
Excessive thirst and frequent urination	Significant hyperglycemia and dehydration	Glucose Test, A1C, and CMP; urgent ketone and emergency testing when severe
Unintended weight loss	Insulin deficiency, thyroid disease, malabsorption, or another systemic condition	Glucose Test, A1C, GAD65 antibodies, IA-2 antibodies, ZnT8 antibodies, clinician-directed C-peptide, TSH and Free T4, and celiac disease screen
Rapidly worsening glucose	Progressive loss of insulin secretion or a classification mismatch	GAD65, IA-2, ZnT8, and C-peptide with concurrent glucose
Short-lived response to type 2 treatment	Possible progressive insulin deficiency; not proof of LADA	Diabetes autoantibodies, C-peptide in the appropriate setting, and glucose trends
Ketones, nausea, vomiting, or abdominal pain	Possible DKA or another acute metabolic problem	Immediate clinical evaluation, blood or urine ketones, electrolytes, and acid-base testing
Fatigue or declining exercise capacity	Hyperglycemia, dehydration, anemia, thyroid dysfunction, iron deficiency, or B12 deficiency	A1C, Glucose Test, CBC, CMP, Ferritin, Iron and Total Iron Binding Capacity, Vitamin B12, and TSH and Free T4
Bloating, diarrhea, constipation, or nutrient deficiency	Celiac disease, malabsorption, medication effects, or another gastrointestinal condition	tTG-IgA, total IgA, CBC, Ferritin, Iron and Total Iron Binding Capacity, Vitamin B12, Folate, and Vitamin D
Neuropathy while taking metformin	Diabetic neuropathy, B12 deficiency, thyroid disease, kidney disease, or another cause	Vitamin B12, CBC, Kidney Profile, and TSH and Free T4; additional testing as directed
Personal or family autoimmune history	Greater clinical suspicion for autoimmune clustering	Diabetes autoantibodies, TSH and Free T4, thyroid antibodies, and symptom-guided celiac or Vitamin B12 testing

Urgent Safety Note

DKA may be the first noticeable sign of autoimmune diabetes. Severe thirst, frequent urination, nausea, vomiting, abdominal pain, profound fatigue, fast or deep breathing, confusion, fainting, or fruity-smelling breath require immediate medical evaluation. A routine laboratory appointment is not appropriate for these symptoms.^[3]

The Role of Lab Testing

Laboratory testing can help answer four different questions:

1. Is glucose abnormally high?
   A1C, fasting glucose, random glucose, and OGTT testing address glucose status.
2. Could the disease be autoimmune?
   GAD65, IA-2, ZnT8, and, in limited circumstances, insulin autoantibodies look for immune markers associated with type 1 diabetes.
3. How much insulin is the pancreas still making?
   C-peptide can estimate endogenous, or internally produced, insulin secretion.
4. Are related organs or conditions affected?
   Kidney Profile, Lipid Panel, TSH and Free T4, celiac disease screen, CBC, and nutritional testing can identify additional issues requiring clinical attention.

Lab testing cannot independently determine the complete diagnosis, prescribe treatment, establish whether insulin should be started or stopped, or explain every atypical diabetes presentation. Autoantibody-negative insulin-deficient diabetes, monogenic diabetes, pancreatic disease, medication-related diabetes, and other atypical forms may require specialist evaluation or genetic and imaging studies.

Results should therefore be interpreted as a pattern—not as isolated numbers. Symptoms, age at onset, body composition, treatment history, medication use, kidney function, glucose at the time of testing, and the duration of diabetes all affect interpretation.

Related Lab Tests and Biomarkers

Tests That Confirm or Classify the Glucose Problem

Test or biomarker	What it measures	Why it may matter	General interpretation	Important limitations
A1C	Percentage of hemoglobin exposed to glucose	Estimates average glycemia over roughly three months	A result of 6.5% or higher is in the diabetes range for nonpregnant adults	Does not classify diabetes; may be misleading with anemia, altered red-cell survival, kidney failure, transfusion, or some hemoglobin variants
Fasting plasma glucose	Blood glucose after an overnight fast	Confirms fasting hyperglycemia	A result of 126 mg/dL or higher is in the diabetes range	Single-point measurement; biological variation and specimen processing time matter
Glucose Tolerance Test, 2 Specimens, 75g	Fasting and two-hour glucose response to a standardized glucose drink	May reveal abnormal glucose regulation not captured by fasting glucose or A1C	Two-hour glucose of 200 mg/dL or higher is in the diabetes range	Requires strict preparation and timed collection; not needed for every patient
GAD65 antibodies	Autoantibodies against glutamic acid decarboxylase	Primary autoantibody recommended when adult type 1 diabetes is suspected	A positive result supports an autoimmune process	A positive result is not interpreted in isolation; low-level positivity can require clinical correlation
IA-2 antibodies	Autoantibodies against islet antigen-2	May provide evidence when GAD is negative but suspicion remains	Positivity supports pancreatic islet autoimmunity	A negative result does not exclude autoimmune diabetes
ZnT8 antibodies	Autoantibodies against zinc transporter 8	Adds sensitivity to an autoimmune diabetes evaluation	Positivity supports islet autoimmunity	Antibody levels can vary with age and disease duration; negative testing is not definitive
Insulin autoantibodies	Antibodies directed against insulin	May support autoimmune classification before insulin treatment	Positivity before treatment may be clinically informative	Externally administered insulin can produce insulin antibodies, limiting usefulness after insulin therapy begins
C-peptide with concurrent glucose	A byproduct released when the pancreas produces insulin	Estimates remaining endogenous insulin production	A low result during adequate or elevated glucose may support insulin deficiency	Early autoimmune diabetes may retain C-peptide; kidney impairment can elevate it; collection and glucose context are essential

The 2026 ADA adult classification pathway recommends GAD as the primary autoantibody, followed by IA-2 and ZnT8 if GAD is negative and suspicion persists. Insulin autoantibodies are most useful in people who have not received insulin. For diabetes classification, the ADA places the main C-peptide role in insulin-treated individuals and recommends concurrent glucose interpretation.^[1]

C-peptide is unaffected by injected insulin and can reflect how much insulin the pancreas is making naturally. Nevertheless, it is not a stand-alone screening test for insulin resistance and should not be used by itself to start, stop, or discontinue insulin.^[5]

Whole-Body Baseline and Comorbidity Tests

Test or biomarker	What it measures	Why it may matter	General high or low findings	Important limitations
CBC	Red cells, white cells, hemoglobin, hematocrit, and platelets	Helps evaluate anemia, infection clues, and fatigue	Low hemoglobin may indicate anemia; cell abnormalities have many possible causes	A normal CBC does not rule out early iron or B12 deficiency
CMP	Glucose, electrolytes, kidney markers, liver markers, proteins, and calcium	Provides a metabolic and organ-function baseline	Abnormal glucose, creatinine, sodium, potassium, bicarbonate, or liver markers may require follow-up	Does not classify diabetes; dehydration and medications can alter results
Lipid Panel	Total, LDL, and HDL cholesterol and triglycerides	Evaluates modifiable cardiovascular risk	High LDL or triglycerides and low HDL may increase risk, depending on the full clinical picture	Cardiovascular decisions depend on age, blood pressure, smoking, kidney health, and other risks
Kidney Profile	Creatinine/eGFR and urine albumin-to-creatinine ratio	Helps identify reduced filtration or albumin leakage before symptoms develop	Higher creatinine, lower eGFR, or persistently elevated urine albumin may indicate kidney injury	Muscle mass, hydration, exercise, infection, menstruation, fever, and marked hyperglycemia can influence results
TSH and Free T4	Pituitary thyroid signaling and circulating thyroid hormone	Type 1 diabetes can cluster with autoimmune thyroid disease	High TSH with low Free T4 may suggest hypothyroidism; other patterns require interpretation	Illness, pregnancy, medications, and supplements such as biotin may affect results
tTG-IgA and total IgA	Celiac-associated antibodies and total IgA status	Useful when digestive symptoms, weight loss, anemia, or nutrient deficiency are present	Positive tTG-IgA supports celiac autoimmunity; low total IgA changes the appropriate antibody strategy	Testing is less reliable after gluten restriction; positive serology usually requires clinical confirmation

ADA guidance recognizes increased thyroid and celiac disease risk in type 1 diabetes and recommends symptom-, sign-, or laboratory-guided celiac screening in adults. Kidney assessment uses both eGFR and urine albumin measurements, while Lipid Panel testing helps identify modifiable cardiovascular risk.^[6]

For accurate celiac serology, the patient generally must still be consuming gluten. Starting a gluten-free diet before testing can reduce antibody levels and produce misleading results.^[7]

Nutritional, Fatigue, and Performance-Related Testing

Test	Why it may be considered	General interpretation and limitations
Vitamin B12	Fatigue, numbness, tingling, balance problems, cognitive symptoms, vegan diets, gastric disease, or long-term metformin use	A low result may indicate deficiency; borderline results may require Methylmalonic Acid or other follow-up. A normal CBC does not exclude neurologic B12 deficiency.
Ferritin and Iron and Total Iron Binding Capacity	Fatigue, reduced endurance, hair loss, anemia, heavy menstrual bleeding, or possible malabsorption	Low Ferritin often reflects depleted iron stores; inflammation can elevate Ferritin and obscure deficiency.
Folate	Anemia, poor dietary intake, malabsorption, or unexplained fatigue	Low levels may contribute to macrocytic anemia; results must be interpreted with Vitamin B12 status.
Vitamin D	Bone-health risk, malabsorption, limited sun exposure, or documented deficiency follow-up	A low result indicates reduced Vitamin D status but does not classify diabetes or explain every fatigue complaint.
Magnesium	Selected cases involving electrolyte loss, gastrointestinal symptoms, or persistent muscle complaints	Serum Magnesium can be useful but may not perfectly represent total-body Magnesium.
Thyroid Peroxidase Antibodies and Thyroglobulin Antibodies	Suspected autoimmune thyroid disease when clinically indicated	Positivity supports thyroid autoimmunity but does not alone establish thyroid dysfunction.
Prolactin, FSH, LH, Estradiol, Testosterone, or SHBG	Menstrual disruption, fertility concerns, low libido, or unexplained muscle loss after glucose and thyroid issues are addressed	These tests do not classify diabetes. Selection and timing should be based on symptoms, sex, menstrual status, medications, and clinician guidance.

Metformin is associated with an increased risk of low Vitamin B12, and the 2026 ADA Standards advise considering periodic Vitamin B12 assessment in people taking metformin chronically, particularly when anemia, neuropathy, or other risk factors are present.^[8]

When to Consider Testing

A discussion about adult-onset autoimmune diabetes testing may be appropriate when an adult with diabetes has an atypical clinical course, especially when several clues occur together.

Testing may be particularly relevant when:

• The diagnosis remains uncertain
• Glucose rises rapidly despite consistent habits
• Weight loss accompanies worsening glucose
• The response to a type 2 treatment strategy is brief or limited
• Insulin becomes necessary sooner than expected
• Ketones or DKA have occurred
• There is a personal or family history of autoimmune disease
• Thyroid symptoms, digestive symptoms, anemia, or nutrient deficiencies persist
• Glucose results and A1C do not agree

Autoantibody testing is not necessary for every adult with type 2 diabetes. The likelihood of gaining useful information is highest when the clinical presentation raises a meaningful classification question.

A Practical Testing Pathway

Level 1: Confirm the Glucose Pattern

Begin with A1C and fasting plasma glucose. An OGTT may be appropriate when fasting glucose and A1C are inconclusive, discordant, or do not match the clinical concern.

Before relying heavily on A1C, consider whether anemia, kidney disease, liver disease, recent transfusion, blood loss, pregnancy, or a hemoglobin variant could be affecting the result.

Level 2: Investigate Autoimmune Diabetes

When the presentation does not fit typical type 2 diabetes, discuss the following approach with a healthcare professional:

1. GAD65 antibodies first
2. IA-2 antibodies and ZnT8 antibodies if GAD is negative and suspicion remains
3. Insulin autoantibodies only when appropriate, especially before insulin exposure
4. A broader Diabetes Type 1 Autoantibody Screening Panel Test or Glutamic Acid Decarboxylase-65, IA2, and Insulin Autoantibodies Panel when a clinician determines that simultaneous testing is preferable

A positive autoantibody result supports an autoimmune classification but does not independently determine treatment. A negative panel also does not completely exclude type 1 diabetes, particularly when severe insulin deficiency or a highly suggestive clinical course is present.^[9]

Level 3: Assess Remaining Insulin Production

A C-peptide test collected with concurrent glucose may help clarify whether the pancreas is still producing a meaningful amount of insulin.

Interpretation depends on:

• The glucose level at the time of collection
• Recent food intake
• Whether the patient uses insulin
• Kidney function
• Diabetes duration
• Recent hypoglycemia or hyperglycemic crisis
• The laboratory method and reference range

C-peptide should not be used alone to choose, reduce, or discontinue insulin.

Level 4: Establish a Whole-Body Baseline

Depending on prior results and clinical history, a baseline may include CBC, CMP, A1C, fasting glucose, Lipid Panel, Kidney Profile, TSH and Free T4, and selected urine testing.

Add symptom-directed testing such as tTG-IgA with total IgA, Vitamin B12, Ferritin, Iron and Total Iron Binding Capacity, Folate, or Vitamin D when digestive problems, anemia, neuropathy, weight loss, weakness, or poor exercise recovery are present.

Level 5: Follow Meaningful Trends

• A1C may be measured twice yearly when glucose is stable and more often—commonly about every three months—when treatment is changing or goals are not being met.
• Lipid Panel results help track cardiovascular risk.
• Kidney Profile results help monitor filtration and urine albumin.
• TSH and Free T4 help identify emerging thyroid dysfunction.
• CBC, Ferritin, Vitamin B12, or Vitamin D may be repeated when following a documented deficiency or persistent symptoms.
• Autoantibodies generally are not repeated simply to monitor glucose control.
• C-peptide is not a routine frequent-monitoring test and should be repeated only when the result would answer a specific classification or insulin-production question.^[10]

How to Understand Your Lab Results

Reference Ranges Are Test-Specific

Reference intervals vary by laboratory method, specimen type, age, sex, pregnancy status, and other factors. Use the range printed on the individual laboratory report rather than a generic online range.

Diagnostic Thresholds Are Not “Optimal” Ranges

The glucose and A1C thresholds used to diagnose diabetes are medical decision limits. They are not personalized treatment goals. Individual glucose targets depend on the type of diabetes, age, pregnancy, other health conditions, hypoglycemia risk, and the management plan.

A Positive Autoantibody Is One Part of the Pattern

A positive GAD65, IA-2, or ZnT8 result supports islet autoimmunity. Interpretation still requires the glucose history, symptoms, treatment course, and sometimes C-peptide or additional evaluation. A single low-level positive result can be less informative when the overall clinical picture does not fit.

A Negative Autoantibody Panel Is Not Always the End of the Evaluation

Antibodies may be undetectable in a minority of people with clinically established type 1 diabetes, and antibody levels can change over time. When insulin deficiency remains strongly suspected, a healthcare professional may consider C-peptide, genetic testing, pancreatic evaluation, or other causes of atypical diabetes.

C-Peptide Must Be Matched to Glucose

A “normal” C-peptide during high glucose may be inappropriately low for the degree of hyperglycemia. Conversely, a higher result can occur with kidney impairment because the kidneys help clear C-peptide. A result without a concurrent glucose value may be difficult to interpret.

Abnormal Does Not Always Mean Disease—and Normal Does Not Always Rule It Out

Dehydration, acute illness, medication use, recent exercise, supplements, pregnancy, and collection conditions can affect results. Repeat testing may be appropriate when a result is unexpected, borderline, inconsistent with symptoms, or likely to have been influenced by a temporary factor.

How Ulta Lab Tests Helps

Ulta Lab Tests allows patients to order many laboratory tests directly online where available, view transparent pricing before ordering, and complete specimen collection through established laboratory networks such as Quest Diagnostics where applicable. Insurance is not required, HSA or FSA payment may be available for eligible services, and results are delivered through a secure online account.

Direct access can make it easier to collect objective information and track meaningful trends. Results should then be shared with a qualified healthcare provider—particularly when glucose is in the diabetes range, an autoantibody is positive, C-peptide is low or difficult to interpret, or symptoms are worsening.

Ulta Lab Tests does not replace medical diagnosis, prescribe treatment, or determine whether a person should begin or change insulin or another medication.

Explore Diabetes Health Tests

View the Type 1 Autoantibody Screening Panel

Preparing for Testing

• A1C: The A1C test itself does not require fasting. A combined order may include tests that do.
• Fasting glucose: Usually requires at least eight hours without food or caloric drinks. Water is generally allowed; follow the specific order instructions.
• OGTT: Requires precise fasting, glucose-drink, and timed-draw instructions. Confirm all preparation requirements before collection.
• Diabetes autoantibodies: Fasting is generally not required unless another test in the order requires it.
• C-peptide: Follow the collection instructions carefully and obtain concurrent glucose when requested. Do not change insulin, medication, food intake, or supplements unless instructed by a healthcare professional.
• Lipid Panel: Some lipid orders require fasting and others do not. Follow the exact preparation instructions.
• Celiac testing: Continue eating gluten before testing unless a qualified healthcare professional has advised otherwise.
• Medications and supplements: Do not stop them on your own. Ask whether insulin, metformin, biotin, steroids, or other products may affect collection or interpretation.
• At the laboratory: Bring the identification and order information listed in the collection confirmation.

Questions to Ask Your Healthcare Provider

1. Does my diabetes course fit type 2 diabetes, or should adult-onset autoimmune diabetes be considered?
2. Should GAD65 be tested first, and would IA-2 or ZnT8 add useful information?
3. Was my insulin autoantibody test collected before or after insulin treatment?
4. Would a C-peptide result be useful and interpretable at this stage?
5. Should C-peptide be collected with fasting or nonfasting glucose?
6. Could kidney function, recent DKA, hypoglycemia, or medication use affect my results?
7. Is my A1C reliable, or could anemia or a hemoglobin issue be distorting it?
8. Should I be evaluated with TSH and Free T4, celiac disease screen, Iron and Total Iron Binding Capacity, Ferritin, or Vitamin B12?
9. Which findings require prompt or emergency follow-up?
10. Which tests should be repeated, and which are unlikely to add value if repeated?

Frequently Asked Questions

Can adults develop type 1 diabetes?

Yes. Type 1 diabetes is more commonly recognized in children and younger adults, but it can begin at any age. Adult symptoms may develop more gradually and resemble type 2 diabetes. Some adults maintain insulin production for months after diagnosis, which can delay recognition of the autoimmune process.^[4]

How is LADA different from type 2 diabetes?

LADA involves autoimmune damage to pancreatic beta cells, while type 2 diabetes is generally characterized by insulin resistance and a progressive inability to produce enough insulin for the body’s needs. Both can cause identical glucose abnormalities, and a person may have features of both. Diabetes autoantibodies help identify autoimmune activity.

What blood tests are used to check for LADA?

Testing usually begins by confirming diabetes with A1C, fasting glucose, random glucose, or an OGTT. When autoimmune diabetes is suspected, GAD65 is the primary autoantibody test. IA-2 and ZnT8 may be added when GAD is negative. C-peptide with concurrent glucose may help assess remaining insulin production in an appropriate clinical setting.

Which diabetes autoantibody should be tested first?

The 2026 ADA Standards identify GAD as the primary antibody to measure when type 1 diabetes is suspected in an adult. If GAD is negative but the presentation remains concerning, IA-2 and ZnT8 may add information. The best strategy depends on prior insulin use, disease duration, symptoms, and treatment history.^[1]

What does a positive GAD65 antibody result mean?

A positive GAD65 result supports the presence of an autoimmune process affecting pancreatic islet cells. It does not, by itself, determine how rapidly insulin production will decline or which treatment is appropriate. The result should be interpreted with glucose measurements, symptoms, disease duration, treatment history, and sometimes additional antibodies or C-peptide.

Can negative autoantibodies rule out adult-onset type 1 diabetes?

No. Negative results make autoimmune diabetes less likely, especially when a complete panel is collected near diagnosis, but they do not eliminate every possibility. Antibodies may be absent or decline over time. Persistent clinical evidence of insulin deficiency may justify C-peptide testing or an endocrinology evaluation for other diabetes types.

What does a C-peptide test show?

C-peptide is released when the pancreas produces insulin, so the result estimates natural insulin secretion even when a person injects insulin. A low result during adequate or elevated glucose can support insulin deficiency. Interpretation must account for glucose, recent food intake, insulin treatment, kidney function, disease duration, and recent metabolic emergencies.

Can A1C distinguish type 1 diabetes from type 2 diabetes?

No. A1C can show that average glucose is elevated and can help diagnose diabetes, but it does not reveal why glucose is high. A person with type 1, type 2, LADA, monogenic diabetes, or another form can have the same A1C. Autoantibodies, C-peptide, history, and clinical assessment help clarify the cause.

Is LADA the same as type 1.5 diabetes?

“Type 1.5 diabetes” is an informal term often used for LADA because the presentation can appear to share features of type 1 and type 2 diabetes. Clinically, LADA is more accurately understood as slowly progressive adult-onset autoimmune diabetes. The term should not replace laboratory classification and professional evaluation.

Can I order LADA laboratory tests without a doctor?

Ulta Lab Tests offers direct online access to many glucose, autoantibody, C-peptide, thyroid, kidney, celiac, and nutritional tests where available. Ordering a test does not replace professional assessment. Autoantibody-positive, low C-peptide, markedly abnormal glucose, or conflicting results should be reviewed promptly with a qualified healthcare provider.

Should diabetes autoantibodies or C-peptide be retested?

Autoantibodies are not routinely repeated to monitor glucose control. Repeat or expanded antibody testing may be useful when the first evaluation was incomplete or performed long after diagnosis. C-peptide may be repeated only when a specific classification question remains and the result would affect clinical decision-making. Retesting should be planned with a provider.

When is high blood sugar an emergency?

Seek immediate medical care for high glucose accompanied by vomiting, abdominal pain, fast or deep breathing, confusion, fainting, profound weakness, dehydration, or fruity-smelling breath. These can be signs of DKA or another hyperglycemic emergency. Do not wait for a routine direct-access laboratory appointment.^[3]

Adult-Onset Autoimmune Diabetes: The Bottom Line

Adult-onset autoimmune diabetes should be considered when a type 2 diabetes diagnosis does not fit the clinical course. Rapid glucose deterioration, unintended weight loss, an unexpectedly early need for insulin, ketones, DKA, or related autoimmune disease can raise suspicion—but no individual clue establishes the diagnosis.

A1C and glucose testing confirm the glucose pattern. GAD65, IA-2, and ZnT8 testing can provide evidence of pancreatic autoimmunity, while appropriately collected C-peptide with concurrent glucose can help assess remaining insulin production. Kidney Profile, Lipid Panel, TSH and Free T4, celiac disease screen, CBC, and nutritional tests add a broader view of health risks and possible causes of persistent fatigue, digestive symptoms, neuropathy, or poor recovery.

Ulta Lab Tests offers convenient direct access to many of these tests through UltaLabTests.com. Explore the Diabetes Health category and relevant autoimmune diabetes tests, follow the preparation instructions for each order, and review abnormal or uncertain findings with a qualified healthcare provider.

A glucose test can show that blood sugar is high. Autoantibody and C-peptide testing can help explain why.

Browse All Diabetes Tests

References

1. American Diabetes Association Professional Practice Committee for Diabetes. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026.
2. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Tests & Diagnosis.
3. Centers for Disease Control and Prevention. Diabetic Ketoacidosis.
4. National Institute of Diabetes and Digestive and Kidney Diseases. Type 1 Diabetes.
5. MedlinePlus. C-Peptide Test.
6. American Diabetes Association Professional Practice Committee for Diabetes. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026.
7. National Institute of Diabetes and Digestive and Kidney Diseases. Celiac Disease Tests.
8. American Diabetes Association Professional Practice Committee for Diabetes. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026.
9. International Expert Panel. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement.
10. American Diabetes Association Professional Practice Committee for Diabetes. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026.
11. National Glycohemoglobin Standardization Program. Factors That Interfere With HbA1c Test Results.
12. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease.

AI Summary for Answer Engines

Adult-onset autoimmune diabetes is type 1 diabetes that begins in adulthood when the immune system damages pancreatic beta cells and insulin production declines. A slower-progressing form is often called LADA and may initially be mistaken for type 2 diabetes.

• Glucose and A1C tests establish whether diabetes is present but do not identify its cause.
• GAD65 is the primary autoantibody recommended when adult type 1 diabetes is suspected.
• IA-2 and ZnT8 may add evidence when GAD is negative and suspicion remains.
• C-peptide with concurrent glucose can help estimate remaining natural insulin production in the appropriate setting.
• Thyroid, celiac, kidney, cardiovascular, and nutritional testing may identify related risks or alternative explanations for symptoms.

Related tests: A1C, fasting glucose, OGTT, GAD65 antibodies, IA-2 antibodies, ZnT8 antibodies, insulin autoantibodies, C-peptide with glucose, CBC, CMP, Lipid Panel, Kidney Profile, TSH and Free T4, tTG-IgA, total IgA, Vitamin B12, Ferritin, Iron and Total Iron Binding Capacity, Folate, and Vitamin D.

How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to many relevant laboratory tests, transparent pricing, established collection networks where applicable, and secure online results.

Disclaimer: Laboratory testing is informational and should be interpreted with symptoms, medical history, and treatment history by a qualified healthcare provider. Urgent symptoms require immediate medical care.